Investopedia
06 Aug 2026, 13:05 UTC · 10w ago
Impact · against what's priced in
Moderna gains a positive catalyst from FDA flu shot approval, while Western Digital and Honeywell face downward pressure following weak quarterly reports. The news represents fundamental updates to revenue potential and immediate growth trajectories for these firms.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
Moderna received FDA approval for its mRNA-based flu shot.
More positive than 94% of claims this week
Western Digital and Sandisk shares are falling following quarterly results.
Continue reading
5 related stories
Poor quarterly results signal immediate weakness in the memory chip sector, driving shares lower.
Read from the article alone
No priced-in read yet
A lackluster earnings report for the Aerospace segment reduces confidence in the company's short-term growth.
Read from the article alone
No priced-in read yet
FDA approval for the mRNA-based flu shot provides a direct catalyst for revenue growth and validates the company's core technology platform.
Read from the article alone
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 90% of claims this week
Honeywell Aerospace shares are declining after a lackluster earnings report.
More negative than 84% of claims this week
SpaceX has reached the expiration of its first lock-up period, increasing the volume of shares available on the market.
More negative than 76% of claims this week
Which stocks this story touches
More positive than 97% of ticker scores this week
Shares are gaining due to FDA approval for its mRNA-based flu shot.
More negative than 85% of ticker scores this week
Shares are tumbling following the release of quarterly results.
More negative than 80% of ticker scores this week
Shares are sinking after a lackluster earnings report.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1h ago
+336.9%
Price agrees with the score
$245.81 vs $56.26 close before publication (Aug 5) · not market-adjusted
MRNA chart →−13.5%
Price agrees with the score
$214.73 vs $248.12 close before publication (Aug 5) · not market-adjusted
HON chart →−27.1%
Price agrees with the score
$378.51 vs $519.17 close before publication (Aug 5) · not market-adjusted
WDC chart →
